Meeting
2024 ASCO Annual Meeting
A phase I/II study of intraperitoneal (IP) paclitaxel (PTX) in patients with metastatic appendiceal adenocarcinoma.
Authors
John Paul Y.C. Shen
The University of Texas MD Anderson Cancer Center, Houston, TX
John Paul Y.C. Shen , Ichiaki Ito , Abdelrahman M.G. Yousef , Michael White , Keith F. Fournier , Beth A Helmink
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Other GI Cancer
Clinical Trial Registration Number
NCT06207305
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr TPS4215)
DOI
10.1200/JCO.2024.42.16_suppl.TPS4215
Abstract #
TPS4215
Poster Bd #
177b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Antitumor activity of intraperitoneal (IP) paclitaxel to mucinous appendiceal adenocarcinoma in orthotopic patient-derived xenograft model.
First Author: Ichiaki Ito
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase I/II study of antroquinonol in combination with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer.
First Author: Yan-Shen Shan
Poster
2018 ASCO Annual Meeting
A phase II study of perioperative intraperitoneal paclitaxel plus S-1/paclitaxel for curatively resectable gastric cancer with serosal invasion: The GAPS study.
First Author: Seiji Ito
Poster
2023 ASCO Annual Meeting
A phase 1 study of concurrent cabozantinib and cetuximab in recurrent or metastatic head and neck squamous cell cancer.
First Author: Antoine Desilets